Search
Pilaralisib
go.drugbank.com/drugs/DB11772InvestigationalPilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and...
Allicin
go.drugbank.com/drugs/DB11780InvestigationalAllicin has been used in trials studying the treatment of Follicular Lymphoma.
Categories: Compounds used in a research, industrial, or household settingLeukotriene D4
go.drugbank.com/drugs/DB11858InvestigationalLeukotriene D4 has been used in trials studying the diagnostic of Asthma and Allergic Rhinitis.
Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-L-cysteinyl)glycine, S-{(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl}-L-cysteinylglycineCategories: SRS-ABrexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalThe development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066]. … In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone)
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Neuroactive Steroid Gamma-Aminobutyric Acid (GABA) A Receptor Positive ModulatorsApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalIn a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigationalLebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older with a
Lesogaberan
go.drugbank.com/drugs/DB11920InvestigationalLesogaberan has been used in trials studying the treatment and basic science of GERD, Reflux, Heartburn, Regurgitation, and Reflux Disease, among others.
Categories: GABA-A Receptor AgonistsSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain o...
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index